2020 Full Year Investor Presentation
Filed with ASX · · 28 pages · English
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26
The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors. Non-IFRS information ● Other than as indicated, the financial information contained in this document is d
Mayne Pharma Group Ltd. on 6ix
In the deck
Story so far
Earlier from Mayne Pharma
- 2020 Full Year Media Release
- Mayne Pharma announces strategic partnership with Novast
- MYX announces FDA filing acceptance of E4/DRSP in the US
- S&P DJI Announces June 2020 Quarterly Rebalance
- MYX signs license agreement for contraceptive in Australia
Later from Mayne Pharma
- Mayne Pharma provides update on Womens Health pipeline
- Chairman and CEOs Addresses to Shareholders
- 2021 Half Year Media Release
- 2021 Half Year Investor Presentation
- FDA approval of novel oral contraceptive NEXTSTELLIS
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma